Flumazenil is used to reverse the effects of benzodiazepine drugs (like valium or similar sedatives) when someone has taken too much or needs to wake up quickly after anesthesia.[2] Romazicon is currently approved and in use across 14 indications[4].[1]
Romazicon is one of 227 small molecule programs targeting Alcohol Dependence. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
137 competitors in Atrial Fibrillation
Romazicon
Calquence
Rituxan
Coumadin
Brukinsa
Imbruvica
Ondexxya
Direct Anticoagulant
SGLT2 Inhibitor
Low-Molecular-Weight Heparin
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Dec 20, 1991
ROMAZICON
NDA NDA020073
Sources
Details